及早发现,诊断,治疗对膀胱癌的预防和治疗具有重要意义。正如许多研究表明的那样,survivin可以作为膀胱癌的生物标志物,而各种研究的结果一直存在争议。本文通过荟萃分析评估survivin在膀胱癌诊断中的准确性。系统检索CNKI文献中关于使用survivin诊断膀胱癌的研究。万方,CBM,VIP,WebofScience,Cochrane图书馆和pubmed被提取,并对文献质量进行了评估。采用STATA16.0MP进行Meta分析。搜索了2,082项相关研究,最终涵盖了40项研究进行荟萃分析。survivinmRNA的合并特异性和合并敏感性分别为0.95(95CI:0.91,0.97)和0.94(95CI:0.88,0.97)。survivin蛋白的合并特异性和合并敏感性分别达到0.95(95CI:0.90,0.97)和0.87(95CI:0.78,0.92)。合并的正似然比,合并负似然比,曲线下的面积,survivinmRNA的诊断比值比达到17.7(95CI:10.3,30.6),0.07(95CI:0.04,0.12),0.98(95CI:0.97,0.99)和266(95CI:114,621),分别。survivin蛋白为16.4(95CI:7.9,33.9),0.14(95CI:0.08,0.24),0.97(95CI:0.95,0.98)和117(95CI:38,357),分别。Survivin在膀胱癌的诊断中具有重要意义。然而,由于覆盖研究的数量和质量存在一些限制,这一结论应通过更高质量的临床研究来验证.
Early detection, diagnosis, and treatment take on critical significance in preventing and treating bladder cancer. As indicated by numerous studies,
survivin can serve as a biomarker of bladder cancer, whereas the results of a wide variety of studies have been controversial. This paper is to assess the accuracy of
survivin in the diagnosis of bladder cancer by a meta-analysis. The studies regarding the diagnosis of bladder cancer using
survivin were systematically retrieved from the CNKI, WanFang, CBM, VIP, Web of science, cochrane library and pubmed were extracted, and the literature quality was assessed. Meta-analysis was conducted using STATA 16.0 MP. 2,082 relevant studies were searched, and 40 studies were finally covered for meta-analysis. The pooled specificity and pooled sensitivity of
survivin mRNA was 0.95 (95%CI: 0.91, 0.97) and 0.94 (95%CI: 0.88, 0.97). The pooled specificity and pooled sensitivity of survivin protein reached 0.95 (95%CI: 0.90, 0.97) and 0.87 (95%CI: 0.78, 0.92). The pooled positive likelihood ratio, pooled negative likelihood ratio, the area under the curve, and diagnostic odds ratio for survivin mRNA reached 17.7 (95%CI: 10.3, 30.6), 0.07 (95%CI: 0.04, 0.12), 0.98 (95%CI: 0.97, 0.99) and 266 (95%CI: 114, 621), respectively. For survivin protein was 16.4 (95%CI: 7.9, 33.9), 0.14 (95%CI: 0.08, 0.24), 0.97 (95%CI: 0.95, 0.98) and 117 (95%CI: 38, 357), respectively.
Survivin takes on great significance in diagnosing bladder cancer. However, due to some limitations in the number and quality of covered studies, this conclusion should be validated through additional higher quality clinical studies.